Latest News

CMS Charity | Love Like Starlight: CMS Continues to Care for Children’s Growth
2026-06-01

CMS Charity | Love Like Starlight: CMS Continues to Care for Children’s Growth

Growing toward the light, together in warmth. With International Children’s Day approaching, China Medical System Holdings Limited (“CMS”), through its subsidiary Shenzhen Kangzhe, continued its long-standing philanthropic initiatives. Via the Charity Association of Shenzhen Nanshan, CMS donated funds to the Star Exceptional Children Rehabilitation Center in Nanshan District, Shenzhen. The donation will be used to upgrade teaching aids, add rehabilitation equipment, and provide support for frontline teachers—helping improve learning, rehabilitation, and living conditions for exceptional children. Over the years, CMS has stood side-by-side with the Center, witnessing every small step of progress in the rehabilitation and growth of these children. This enduring commitment stems from a deep compassion for special-needs children and a profound understanding of philanthropic values: their development demands patience, sustained support, and collective care from society. In addition, CMS donated 10 computers to the Green & Shine Foundation to help improve educational facilities in schools across central and western China, supporting daily teaching […]

Learn More
CMS Wins Dual Honors at the 2026 “Golden Kunpeng”: “Best Listed Company” and “Most Investable Listed Company”
2026-05-27

CMS Wins Dual Honors at the 2026 “Golden Kunpeng”: “Best Listed Company” and “Most Investable Listed Company”

On 26 May 2026, the 2026 Global Commercial Newspaper Economic Forum and the “Golden Kunpeng” China Financial Value Ranking Awards Ceremony, co-hosted by the Global Commercial Newspaper Alliance and Hong Kong Commercial Daily, was held in Hong Kong. China Medical System Holdings Limited (“CMS” or the “Group”) stood out among a broad field of participating companies on the strength of its solid fundamentals and sustainable growth outlook, winning two awards: “Best Listed Company” and “Most Investable Listed Company”. Meanwhile, based on the Group’s overall performance in innovative R&D, growth and liquidity, the Group was officially included as a constituent of the Hong Kong Commercial Daily Technology Index.     The “Best Listed Company” award provides a comprehensive assessment across core indicators including financial performance, corporate governance, ESG practices and market influence, while the “Most Investable Listed Company” award focuses on dimensions such as the sustainability of the business model, financial soundness and industry growth potential. […]

Learn More
China Medical System’s Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Ulcerative Colitis and Crohn’s Disease
2026-05-26

China Medical System’s Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Ulcerative Colitis and Crohn’s Disease

  CMS-D001 is an oral highly selective TYK2 inhibitor. It can reduce the impact on other JAK family kinases, and is expected to lower safety risks while maintaining efficacy.   Currently, no TYK2 inhibitor has been approved globally for the indications of ulcerative colitis and Crohn’s disease. CMS-D001 proactively positions in the gastroenterologytherapeutic area, and is expected to become an emerging oral therapy for ulcerative colitis and Crohn’s disease; it can synergise with the Group’s marketed products Salofalk and the exclusive product Bioflor, strengthening whole-cycle, whole-disease-course management of intestinal diseases, and enhancing the Group’s competitive position in the gastroenterology therapeutic area.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, on 22 May 2026, the innovative drug highly selective TYK2 (tyrosine kinase 2) inhibitor CMS-D001 Tablets (“CMS-D001” or the “Product”) has been granted the Drug Clinical Trial Approval Notice by the National Medical Products Administration of the People’s Republic […]

Learn More

The news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.

All News

CMS Charity | Love Like Starlight: CMS Continues to Care for Children’s Growth
2026-06-01
CMS Wins Dual Honors at the 2026 “Golden Kunpeng”: “Best Listed Company” and “Most Investable Listed Company”
2026-05-27
China Medical System’s Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Ulcerative Colitis and Crohn’s Disease
2026-05-26
CMS 34th Anniversary | Moving with Time, Growing for Tomorrow
2026-05-13
CMS Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®
2026-04-27
CMS: NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China
2026-04-23
CMS Included in S&P Global Sustainability Yearbook (China Edition) for the Fourth Consecutive Year
2026-04-14
Performance Returns to Growth Trajectory丨CMS (867.HK, 8A8.SG) 2025 Annual Performance Report in One Picture
2026-03-16
CMS: New Drug for Renal Anaemia Desidustat Tablets Approved in China
2026-03-13
CMS : Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
2026-03-12